Literature DB >> 15034008

IL-2, regulatory T cells, and tolerance.

Brad H Nelson1.   

Abstract

IL-2 is a potent T cell growth factor that for many years was assumed to amplify lymphocyte responses in vivo. Accordingly, IL-2 has been used clinically to enhance T cell immunity in patients with AIDS or cancer, and blocking Abs to the IL-2R are used to inhibit T cell responses against transplanted tissues. It was later shown in mice that, unexpectedly, disruption of the IL-2 pathway results in lymphoid hyperplasia and autoimmunity rather than immune deficiency, indicating that the major physiological function of IL-2 is to limit rather than enhance T cell responses. This apparent paradox has recently been resolved with the discovery that IL-2 is critical for the development and peripheral expansion of CD4(+)CD25(+) regulatory T cells, which promote self-tolerance by suppressing T cell responses in vivo. Our new understanding of IL-2 biology prompts a re-evaluation of how best to clinically manipulate this important immunoregulatory pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034008     DOI: 10.4049/jimmunol.172.7.3983

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  194 in total

Review 1.  The role of melatonin in immuno-enhancement: potential application in cancer.

Authors:  Sandra C Miller; S R Pandi-Perumal; Perumal S R Pandi; Ana I Esquifino; Daniel P Cardinali; Georges J M Maestroni
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

Review 2.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

Review 4.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

5.  Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Authors:  Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 6.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 7.  The melatonin-cytokine connection in rheumatoid arthritis.

Authors:  M Cutolo; G J M Maestroni
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

10.  Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

Authors:  Aruna Gowda; Asha Ramanunni; Carolyn Cheney; Darlene Rozewski; Wayne Kindsvogel; Amy Lehman; David Jarjoura; Michael Caligiuri; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2010-01-08       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.